We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
- Authors
Khuri, Fadlo R; Lee, J Jack; Lippman, Scott M; Kim, Edward S; Cooper, Jay S; Benner, Steven E; Winn, Rodger; Pajak, Thomas F; Williams, Brendell; Shenouda, George; Hodson, Ian; Fu, Karen; Shin, Dong M; Vokes, Everett E; Feng, Lei; Goepfert, Helmuth; Hong, Waun Ki
- Abstract
Isotretinoin (13-cis-retinoic acid) is a synthetic vitamin A derivative, or retinoid, widely used in the treatment of cystic acne. Preclinical and clinical studies of high-dose isotretinoin in patients with head and neck squamous cell cancer (HNSCC) have produced encouraging results. We conducted a phase III randomized trial of low-dose isotretinoin versus placebo in early-stage HNSCC patients to assess its effect on second primary tumor incidence and survival.
- Publication
Journal of the National Cancer Institute, 2006, Vol 98, Issue 7, p441
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djj091